Doximity's stock surged up to 105% in premarket trading on August 7, 2026, after the company raised its full-year guidance on the back of a tenfold increase in AI scribe usage and a strong showing in an independent clinical AI safety study (Tech Times).

The dual catalysts landed on the heels of Doximity's fiscal 2027 first-quarter earnings release, which had been scheduled for August 6, 2026 (Doximity Investor Relations). The same day, Doximity announced that its clinical AI outranked OpenEvidence and frontier models in an independent Stanford-Harvard study of clinical AI safety (Doximity Press).

The guidance raise directly ties to product traction. AI scribe usage surged tenfold, a metric that signals genuine adoption rather than pilot-stage curiosity. For a digital health platform whose revenue model depends on physician engagement and pharma marketing spend flowing through that engagement, a tenfold usage ramp in a single product line is the kind of inflection that re-rates expectations.

The Stanford-Harvard safety study adds a second, qualitatively distinct lever. Clinical AI tools live or die on trust. Outranking frontier models from well-funded competitors in an independent academic evaluation gives Doximity a defensible positioning claim in a category where most vendors rely on self-reported benchmarks. The study was announced August 6, 2026, the same day as the scheduled earnings release.

For market participants, the 105% premarket move reflects a repricing of both near-term fundamentals and the narrative around Doximity's AI positioning. The guidance raise anchors the move in cash-flow reality rather than pure sentiment. The safety study result extends the thesis into a moat argument: if Doximity's clinical AI is independently validated as safer than alternatives, switching costs and referral patterns in the physician workflow compound from there.

The broader context here is that digital health AI applications have faced persistent skepticism about whether clinical-grade tools can translate into durable revenue. Doximity's announcement bundles two answers in one cycle: adoption (tenfold usage) and validation (topping a Stanford-Harvard safety study). The market's initial reaction suggests participants are weighting both signals heavily.

Whether the premarket gap holds into the regular session will depend on the specifics embedded in the raised guidance, the Q1 print, and management's commentary on the sustainability of AI scribe growth rates. Premarket moves of this magnitude often see profit-taking at the open, and the gap between a 105% premarket surge and a settled close will be the first read on how much conviction backs the repricing.

The competitive angle warrants attention. OpenEvidence and frontier models are not trivial competitors to outrank in a safety evaluation. If the Stanford-Harvard methodology and data hold up under scrutiny, Doximity's result could pressure competitors' clinical AI roadmaps and elevate the bar for what constitutes credible safety validation in this category. That said, a single study, however prestigious the institutional backing, is one data point. Replication and broader evaluation across additional institutions and clinical domains will matter for whether the positioning claim hardens into a durable advantage.